Nab-paclitaxel (Abraxane)
Showing 1 - 25 of 3,495
Metastatic Breast Cancer Trial in New York (PU-H71, Nab-paclitaxel)
Completed
- Metastatic Breast Cancer
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Dec 17, 2021
Mesothelioma Trial run by the National Cancer Institute (NCI) (LMB-100, nab-paclitaxel)
Completed
- Mesothelioma
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jul 28, 2022
HR+/HER2- Breast Cancer Trial (Tucidinostat, nab-paclitaxel)
Not yet recruiting
- HR+/HER2- Breast Cancer
- (no location specified)
Nov 21, 2022
Pancreatic Cancer Trial in Boston, Philadelphia (Gemcitabine, Nab-paclitaxel, Paricalcitol)
Active, not recruiting
- Pancreatic Cancer
- Gemcitabine
- +3 more
-
Boston, Massachusetts
- +1 more
Jan 9, 2023
Breast Cancer Trial in Boston (Pembrolizumab, Nab-Paclitaxel, Biopsy)
Active, not recruiting
- Breast Cancer
- Pembrolizumab
- +2 more
-
Boston, MassachusettsDana-Farber Cancer Institute
Aug 22, 2022
Solid Tumors Trial in United States (CORT125134 with nab-paclitaxel)
Completed
- Solid Tumors
- Relacorilant with nab-paclitaxel
-
Scottsdale, Arizona
- +3 more
Nov 9, 2022
Pancreatic Adenocarcinoma, Resectable Pancreatic Cancer Trial (Nab paclitaxel, Gemcitabine, NovoTTF-200T)
Not yet recruiting
- Pancreatic Adenocarcinoma
- Resectable Pancreatic Cancer
- Nab paclitaxel
- +2 more
- (no location specified)
Dec 5, 2022
Pancreatic Cancer, Stage IB, Pancreatic Cancer, Stage IIA, Pancreatic Cancer, Stage IIB Trial in Shanghai (sintilimab,
Not yet recruiting
- Pancreatic Cancer, Stage IB
- +3 more
- sintilimab
- +2 more
-
Shanghai, Shanghai, ChinaZhongshan Hospital
Jan 4, 2023
Nab-Paclitaxel in Combination With Carboplatin as First-line
Completed
- Carcinoma, Non-Small-Cell Lung
-
Freiburg, Baden-Württemberg, GermanyiOMEDICO
Oct 5, 2021
Pancreatic Acinar Cell Carcinoma, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma Trial (Nab paclitaxel,
Not yet recruiting
- Pancreatic Acinar Cell Carcinoma
- +6 more
- Nab paclitaxel
- +5 more
- (no location specified)
Oct 30, 2023
Breast Cancer Trial in Houston (Panitumumab, Nab-paclitaxel, Carboplatin)
Completed
- Breast Cancer
- Panitumumab
- +5 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Sep 20, 2022
Triple Negative Breast Cancer Metastatic Trial in Milano, Padova (Ceralasertib, Durvalumab, Nab-paclitaxel)
Recruiting
- Triple Negative Breast Cancer Metastatic
- Ceralasertib
- +2 more
-
Milano, Italy
- +1 more
Jan 16, 2023
Metastatic Pancreatic Adenocarcinoma Trial in Madrid (nab-paclitaxel, gemcitabine, m-FOLFOX)
Completed
- Metastatic Pancreatic Adenocarcinoma
- nab-paclitaxel
- +2 more
-
Madrid, SpainSpanish Cooperative for Digestive Tumour Therapy (TTD)
Aug 11, 2021
Aggressive Non-Hodgkin Lymphoma, CD20 Positive, Recurrent B-Cell Non-Hodgkin Lymphoma Trial in Rochester (Laboratory Biomarker
Suspended
- Recurrent Aggressive Non-Hodgkin Lymphoma
- +5 more
- Laboratory Biomarker Analysis
- +2 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 12, 2023
NSCLC Metastatic Trial (Atezolizumab, Nab paclitaxel, Carboplatin)
Not yet recruiting
- Non-Small Cell Lung Cancer Metastatic
- Atezolizumab
- +5 more
- (no location specified)
Jan 18, 2023
KRAS Activating Mutation, Metastatic Cancer, Pancreas Cancer Trial in Saint Louis (avutometinib (VS-6766) and defactinib in
Recruiting
- KRAS Activating Mutation
- +4 more
- avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel
-
Saint Louis, MissouriWashington University School of Medicine
Jan 3, 2023
Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma Trial in United States (Laboratory
Active, not recruiting
- Locally Advanced Breast Carcinoma
- +7 more
- Laboratory Biomarker Analysis
- +2 more
-
Duarte, California
- +3 more
Jan 31, 2023
Pancreas Cancer Trial in Houston (Gemcitabine, Nab paclitaxel, IM156)
Not yet recruiting
- Pancreas Cancer
- Gemcitabine
- +2 more
-
Houston, TexasMD Anderson Cancer Center
Aug 15, 2022
Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic
Active, not recruiting
- Breast Cancer
-
New York, New YorkNYU Perlmutter Cancer Center
Aug 5, 2022
Pancreatic Ductal Adenocarcinoma Trial in Saint Louis (BMS-813160, Nivolumab, Gemcitabine)
Active, not recruiting
- Pancreatic Ductal Adenocarcinoma
- BMS-813160
- +5 more
-
Saint Louis, MissouriWashington University School of Medicine
Dec 8, 2022
NSCLC Trial in Boston, New York (MPDL3280A, Carboplatin, Nab-paclitaxel)
Completed
- Carcinoma, Non-Small-Cell Lung
- MPDL3280A
- +2 more
-
Boston, Massachusetts
- +1 more
Oct 12, 2022
Triple Negative Breast Cancer, Locally Advanced Breast Cancer, Unresectable Breast Carcinoma Trial in Aurora (Nab-paclitaxel,
Withdrawn
- Triple Negative Breast Cancer
- +4 more
- Nab-paclitaxel
- +3 more
-
Aurora, ColoradoUniversity of Colorado Hospital
Dec 2, 2022